SLC5A2 and hydrops fetalis: When pooled analysis was performed for RCTs that used EF ≥ 50 % for the diagnosis of HFpEF, SGLT-2 inhibitors reduced the risk of a composite of hospitalization for HF and CV death (HR [95 % CI] = 0.70 [0.56, 0.88], Pfix = 0.002; heterogeneity, P = 0.34, I2 = 6.8 %) but not the risk of all-cause death (OR [95 % CI] = 1.08 [0.70, 1.65], Pfix = 0.73; heterogeneity, P = 1.0, I2 = 0 %; supplemental Fig. 4).